Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Dec

Today In Oncology

Adding Durvalumab to Chemoradiotherapy in Locally Advanced Cervical Cancer

First-Line Treatment of Advanced HCC Addition of Pembrolizumab to Lenvatinib

Everolimus for Pediatric Recurrent/Progressive Low-Grade Glioma

Chronic Health Conditions May Be Prevalent Among LGB Adolescent and Young Adult Cancer Survivors

Lung-MAP Trial Demonstrates Potential of Public-Private Partnerships in Advancement of Cancer Therapy

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Adding Durvalumab to Chemoradiotherapy in Locally Advanced Cervical Cancer

First-Line Treatment of Advanced HCC Addition of Pembrolizumab to Lenvatinib

Everolimus for Pediatric Recurrent/Progressive Low-Grade Glioma

Chronic Health Conditions May Be Prevalent Among LGB Adolescent and Young Adult Cancer Survivors

Lung-MAP Trial Demonstrates Potential of Public-Private Partnerships in Advancement of Cancer Therapy